ABT 491 Hydrochloride

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 524107

CAS#: 189689-94-9

Description: ABT-491 hydrochloride is a highly potent, selective and orally active platelet-activating factor receptor (PAF-R) antagonist.


Price and Availability

Size
Price

Size
Price

Size
Price

ABT 491, purity > 98%, is not in stock, may be available through custom synthesis. Minimum 1 gram order is requested. Current shipping out time is about 70 days after order is received.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 524107
Name: ABT 491 Hydrochloride
CAS#: 189689-94-9
Chemical Formula: C28H23ClFN5O2
Exact Mass:
Molecular Weight: 515.97
Elemental Analysis: C, 65.18; H, 4.49; Cl, 6.87; F, 3.68; N, 13.57; O, 6.20


Synonym: ABT 491 hydrochloride; ABT 491; ABT-491; ABT491;

IUPAC/Chemical Name: 1H-Indole-1-carboxamide, 4-ethynyl-3-(3-fluoro-4-((2-methyl-1H-imidazo(4,5-c)pyridin-1-yl)methyl)benzoyl)-N,N-dimethyl-, monohydrochloride

InChi Key: AWRGBOKANQBIBM-UHFFFAOYSA-N

InChi Code: InChI=1S/C28H22FN5O2.ClH/c1-5-18-7-6-8-25-26(18)21(16-34(25)28(36)32(3)4)27(35)19-9-10-20(22(29)13-19)15-33-17(2)31-23-14-30-12-11-24(23)33;/h1,6-14,16H,15H2,2-4H3;1H

SMILES Code: O=C(N1C=C(C(C2=CC=C(CN3C(C)=NC4=C3C=CN=C4)C(F)=C2)=O)C5=C1C=CC=C5C#C)N(C)C.[H]Cl


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


References

1: Xu B, Gao L, Wang L, Tang G, He M, Yu Y, Ni X, Sun Y. Effects of
platelet-activating factor and its differential regulation by androgens and
steroid hormones in prostate cancers. Br J Cancer. 2013 Sep 3;109(5):1279-86.
doi: 10.1038/bjc.2013.480. Epub 2013 Aug 15. PubMed PMID: 23949154; PubMed
Central PMCID: PMC3778313.

2: Keating FK, Schneider DJ. The influence of platelet activating factor on the
effects of platelet agonists and antiplatelet agents in vitro. J Thromb
Thrombolysis. 2009 Jul;28(1):38-45. doi: 10.1007/s11239-008-0239-5. Epub 2008 Jun
25. PubMed PMID: 18574670.

3: Bozlu G, Atici A, Turhan AH, Polat A, Nayci A, Okuyaz C, Taskinlar H.
Platelet-activating factor antagonist (ABT-491) decreases neuronal apoptosis in
neonatal rat model of hypoxic ischemic brain injury. Brain Res. 2007 Apr
27;1143:193-8. Epub 2007 Feb 1. PubMed PMID: 17320823.

4: Reyes YA, Shimoyama T, Akamatsu H, Sunamori M. MCI-186 (edaravone), a free
radical scavenger, attenuates ischemia-reperfusion injury and activation of
phospholipase A(2) in an isolated rat lung model after 18 h of cold preservation.
Eur J Cardiothorac Surg. 2006 Mar;29(3):304-11. Epub 2006 Jan 19. PubMed PMID:
16427299.

5: Curtin ML, Davidsen SK, Heyman HR, Garland RB, Sheppard GS, Florjancic AS, Xu
L, Carrera GM Jr, Steinman DH, Trautmann JA, Albert DH, Magoc TJ, Tapang P, Rhein
DA, Conway RG, Luo G, Denissen JF, Marsh KC, Morgan DW, Summers JB. Discovery and
evaluation of a series of 3-acylindole imidazopyridine platelet-activating factor
antagonists. J Med Chem. 1998 Jan 1;41(1):74-95. PubMed PMID: 9438024.

6: Albert DH, Malo PE, Tapang P, Shaughnessy TK, Morgan DW, Wegner CD, Curtin ML,
Sheppard GS, Xu L, Davidsen SK, Summers JB, Carter GW. The role of
platelet-activating factor (PAF) and the efficacy of ABT-491, a highly potent and
selective PAF antagonist, in experimental allergic rhinitis. J Pharmacol Exp
Ther. 1998 Jan;284(1):83-8. PubMed PMID: 9435164.

7: Albert DH, Tapang P, Morgan DW, Curtin ML, Sheppard GS, Davidsen SK, Summers
JB, Carter GW. ABT-491, a highly potent and selective PAF antagonist, inhibits
nasal vascular permeability associated with experimental allergic rhinitis in
brown Norway rats. Inflamm Res. 1997 Aug;46 Suppl 2:S133-4. PubMed PMID: 9297547.

8: Albert DH, Magoc TJ, Tapang P, Luo G, Morgan DW, Curtin M, Sheppard GS, Xu L,
Heyman HR, Davidsen SK, Summers JB, Carter GW. Pharmacology of ABT-491, a highly
potent platelet-activating factor receptor antagonist. Eur J Pharmacol. 1997 Apr
23;325(1):69-80. PubMed PMID: 9151941.